'Magic Mushrooms' Effective for Severe Depression Batya Swift Yasgur, MA, LSW Medscape, October 20, 2017 https://www.medscape.com/viewarticle/887384 Psilocybin, the psychoactive compound in “magic mushrooms,” is a promising intervention for patients with treatment-resistant depression (TRD) and appears to offer a rapid, sustained effect, new research shows. Investigators led by David Nutt, MD, PhD, professor of neuropsychopharmacology, Imperial College, London, United Kingdom, collected pre- and posttreatment fMRI data on the use of psilocybin in 19 patients with severe major depression who had failed to respond to conventional treatments. The patients experience dramatic improvements in depressive symptoms 1 day following treatment; close to half met criteria for full response at [...]
Lire la suitePsychedelic Cuts Cravings, Consumption in Alcohol Use Disorder Pauline Anderson Medscape, May 23, 2019 https://www.medscape.com/viewarticle/913422?src=wnl_tp10n_190711_mscpedit&uac=292598PZ&impID=2023688&faf=1 SAN FRANCISCO — Just two doses of the psychedelic drug psilocybin, taken over a period of 8 weeks, significantly reduced alcohol use and cravings in patients with alcohol use disorder, preliminary findings show. In the first study to use modern clinical trial design to investigate the effects of a hallucinogen in alcohol-dependent patients, investigators at New York University (NYU) School of Medicine in New York City found that use of psilocybin was significantly associated with fewer drinking days and fewer drinks per day, as well fewer cravings. Dr Kelley Clark O'Donnell "Psychedelic [...]
Lire la suiteFirst, Marijuana. Are Magic Mushrooms Next ? Barbara Feder Ostrov Medscape - May 21, 2018 In Oregon and Denver, where marijuana is legal for recreational use, activists are now pushing toward a psychedelic frontier: “magic mushrooms.” Groups in both states are sponsoring ballot measures that would eliminate criminal penalties for possession of the mushrooms whose active ingredient, psilocybin, can cause hallucinations, euphoria and changes in perception. They point to research showing that psilocybin might be helpful for people suffering from depression or anxiety. “We don’t want individuals to lose their freedom over something that’s natural and has health benefits,” said Kevin Matthews, the campaign director [...]
Lire la suiteNovel insights into mitochondrial molecular targets of iron-inducedneurodegeneration: Reversal by cannabidiol Vanessa Kappel da Silva, Betânia Souza de Freitas, Victória Campos Dornelles,Luiza Wilges Kist, Maurício Reis Bogoc, Milena Carvalho Silvad, Emílio Luiz Streck, Jaime Eduardo Hallak, Antônio Waldo Zuardib,e, José Alexandre S. Crippab,e,Nadja Schrödera Brain Research Bulletin, 2018, 139, 1–8 https://doi.org/10.1016/j.brainresbull.2018.01.014 ABSTRACT Evidence has demonstrated iron accumulation in specific brain regions of patients suffering from neurodegen-erative disorders, and this metal has been recognized as a contributing factor for neurodegeneration. Using anexperimental model of brain iron accumulation, we have shown that iron induces severe memory deficits thatare accompanied by oxidative stress, increased apoptotic markers, and decreased [...]
Lire la suiteThe neuroprotection of cannabidiol against MPP+-induced toxicity inPC12 cells involves trkA receptors, upregulation of axonal and synapticproteins, neuritogenesis, and might be relevant to Parkinson's disease Neife Aparecida Guinaim Santos, Nádia Maria Martins, Flávia Malvestio Sisti, Laís Silva Fernandes, Rafaela Scalco Ferreira, Regina Helena Costa Queiroz, Antônio Cardozo Santos Toxicology in Vitro, 2015, 30, 231–240. http://dx.doi.org/10.1016/j.tiv.2015.11.004 a b s t r a c t Cannabidiol (CBD) is a non-psychoactive constituent of Cannabis sativa with potential to treat neurodegenerative diseases. Its neuroprotection has beenmainly associated with anti-inflammatory and antioxidant events; however, other mechanisms might be involved. We investigated the involvement of neuritogenesis, NGF receptors (trkA), NGF, and [...]
Lire la suiteCannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis : A role for A2A receptors M. Mecha, A. Feliú, P.M. Iñigo, L. Mestre, F.J. Carrillo-Salinas, C. Guaza Neurobiology of Disease, 2013, 59, 141–150 https://doi.org/10.1016/j.nbd.2013.06.016 Inflammation in the central nervous system (CNS) is a complex process that involves a multitude of mole-cules and effectors, and it requires the transmigration of blood leukocytes across the blood–brain barrier(BBB) and the activation of resident immune cells. Cannabidiol (CBD), a non-psychotropic cannabinoid constituent of Cannabis sativa, has potent anti-inflammatory and immunosuppressive properties. Yet, how this compound modifies the deleterious effects of [...]
Lire la suiteEvidences for the Anti-panic Actions of Cannabidiol Vanessa P. Soares and Alline C. Campos Current Neuropharmacology, 2017, 15, 291-299 DOI : 10.2174/1570159X14666160509123955 Abstract : Background : Panic disorder (PD) is a disabling psychiatry condition that affects approximately 5% of the worldwide population. Currently, long-term selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for PD; however, the common side-effect profiles and drug interactions may provoke patients to abandon the treatment, leading to PD symptoms relapse. Cannabidiol (CBD) is the major non-psychotomimetic constituent of the Cannabis sativa plant with antianxiety properties that has been suggested as an alternative for treating anxiety disorders. The aim of the [...]
Lire la suiteNeuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on b-amyloid-induced toxicity in PC12 cells Teresa Iuvone, Giuseppe Esposito, Ramona Esposito, Rita Santamaria, Massimo Di Rosa and Angelo A. Izzo Journal of Neurochemistry, 2004, 89, 134–141 doi:10.1111/j.1471-4159.2003 Abstract Alzheimer’s disease is widely held to be associated with oxidative stress due, in part, to the membrane action of b-amyloid peptide aggregates. Here, we studied the effect of cannabidiol, a major non-psychoactive component of the marijuana plant (Cannabis sativa) on b-amyloid peptide-induced toxicity in cultured rat pheocromocytoma PC12 cells. Following exposure of cells to b-amyloid peptide (1 lg/mL), a marked reduction in cell survival was observed. This effect [...]
Lire la suiteCannabis sativa : The Plant of the Thousand and One Molecules Christelle M. Andre, Jean-Francois Hausman and Gea Guerriero Frontiers in Plant Science, 2016, Volume 7, Article 19. doi:10.3389/fpls.2016.00019 Cannabis sativa L. is an important herbaceous species originating from Central Asia, which has been used in folk medicine and as a source of textile fiber since the dawn of times. This fast-growing plant has recently seen a resurgence of interest because of its multi-purpose applications : it is indeed a treasure trove of phytochemicals and a rich source of both cellulosic and woody fibers. Equally highly interested in this plant are the pharmaceutical and [...]
Lire la suiteThe diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids : D9-tetrahydrocannabinol, cannabidiol and D9-tetrahydrocannabivarin Roger G. Pertwee British Journal of Pharmacology, 2008, 153, 199–215 doi:10.1038/sj.bjp.0707442 Cannabis sativa is the source of a unique set of compounds known collectively as plant cannabinoids or phytocannabinoids. This review focuses on the manner with which three of these compounds, (-)-trans-D9-tetrahydrocannabinol (D9-THC), (-)- cannabidiol (CBD) and (-)-trans-D9-tetrahydrocannabivarin (D9-THCV), interact with cannabinoid CB1 and CB2 receptors. D9-THC, the main psychotropic constituent of cannabis, is a CB1 and CB2 receptor partial agonist and in line with classical pharmacology, the responses it elicits appear to be strongly influenced both by [...]
Lire la suite